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Abstract
Background: Mutations in the GJB2 gene have been established as a major cause of inherited non
syndromic deafness in different populations. A high number of sequence variations have been
described in the GJB2 gene and the associated pathogenic effects are not always clearly established.
The prevalence of a number of mutations is known to be population specific, and therefore
population specific testing should be a prerequisite step when molecular diagnosis is offered.
Moreover, population studies are needed to determine the contribution of GJB2  variants to
deafness. We present our findings from the molecular diagnostic screening of the GJB2 and GJB6
genes over a three year period, together with a population-based study of GJB2 variants.
Methods and results: Molecular studies were performed using denaturing High Performance
Liquid Chromatograghy (DHPLC) and sequencing of the GJB2 gene. Over the last 3 years we have
studied 159 families presenting sensorineural hearing loss, including 84 with non syndromic, stable,
bilateral deafness. Thirty families were genotyped with causative mutations. In parallel, we have
performed a molecular epidemiology study on more than 3000 dried blood spots and established
the frequency of the GJB2 variants in our population. Finally, we have compared the prevalence of
the variants in the hearing impaired population with the general population.
Conclusion: Although a high heterogeneity of sequence variation was observed in patients and
controls, the 35delG mutation remains the most common pathogenic mutation in our population.
Genetic counseling is dependent on the knowledge of the pathogenicity of the mutations and
remains difficult in a number of cases. By comparing the sequence variations observed in hearing
impaired patients with those sequence variants observed in general population, from the same
ethnic background, we show that the M34T, V37I and R127H variants can not be responsible for
profound or severe deafness.
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Background
The genetic origin of deafness is suspected in more than
half of the congenital hearing loss cases. More than 400
syndromes can include hearing loss or deficient hearing
functions as a component. However, non syndromic
expression of deafness is observed in more than 70 % of
cases. In the non syndromic forms of hearing loss
(NSHL), familial or sporadic cases are observed and the
transmission is predominantly autosomal recessive.
Genetic heterogeneity has been established by linkage
studies: more that 50 loci associated with NSHL (includ-
ing dominant and recessive autosomal, and X-linked
types of transmission) have been localized, making possi-
ble the identification of a number of causative deafness
genes http://dnalab-www.uia.ac.be/dnalab/hhh/. Despite
the extreme genetic heterogeneity, the recessive DFNB1
locus, mapping to chromosome 13q12, is by far the most
prevalent. This locus contains the two Gap junction genes
GJB2  and  GJB6, encoding, respectively connexin 26
(CX26) and connexin 30 (CX30). These proteins associate
in hexamers to form homo- and hetero-connexons [1,2].
Two connexons from adjacent cells dock to form a func-
tional channel that will allow, among other small mole-
cules, the diffusion of potassium ions critical for the
normal sensory hair cell excitation [3].
The contribution of the GJB2 gene in NSHL varies from 0
to 40 % in diverse populations [4] and this genetic heter-
ogeneity is also emphasized by the variation in frequency
of specific mutations among different populations. More
than 70 mutations in the GJB2 gene have been reported
[5], and although the majority are rare or private, the prev-
alence of four mutations define specific ethnic origins.
The 35delG mutation accounts for approximately 70 % of
GJB2 mutant alleles in Northern and Southern European,
as well as American Caucasian populations, with a carrier
frequency of 2.3 % to 4 % [6-9]. The three other muta-
tions, 167delT, 235delC or R143W represent the most
common pathogenic alleles in Ashkenazi Jews [10], Asian
[11-14] and Ghanian populations [15,16], respectively.
Recently, we and other groups have identified a large 309
kb deletion that includes the 5' region of the GJB6 gene
and most of its coding region [17]. It is unclear whether
this deletion removes regulatory elements common to
GJB6 and GJB2 resulting, in addition to the deletion of
GJB6, in reduced expression of the wild type GJB2 gene
[17-20]. This deletion also appears to have an ethnic spe-
cific origin as it is absent from the Siberian (manuscript in
preparation), Chinese [21], Austrian and Italian popula-
tions [17,22]. In this report, when we refer to GJB6 muta-
tions we will consider only this particular mutation
∆(GJB6-D13S1830).
Molecular diagnostic testing of non syndromic deafness
was initiated in Montpellier in early 2000. This testing was
carried out in parallel with a molecular epidemiology
study of GJB2  variants in the Languedoc Roussillon
region. Although many reports have estimated the carrier
frequency in French and Mediterranean populations
(mostly of the 35delG mutation), differences of frequency
between samples are observed (0.0 to 2.7 % in France).
This is essentially due to the size and composition of con-
trol samples [23]; for review see [4]. Assessment of GJB2
variant sequence distribution in Languedoc Roussillon
was necessary, as we had observed significant differences
in the distribution of CFTR mutations between several
French regions [24].
In this study, we present our results from three years of
molecular diagnostic testing of GJB2/GJB6 including the
clinical and associated audiologic findings and also deter-
mine the prevalence and spectrum of DFNB1 mutations
in the southern France population. In addition, we report
the first screening of the most frequent GJB2 variants, on
several thousand dried bloodspots (Guthrie cards) from
newborns and thus re-evaluate the pathogenic status of
some GJB2 variants.
Methods
Patients
A total of 159 unrelated families, comprised of 184
patients with sensorineural hearing loss, were referred
from the Genetic Counseling Department and/or the Ear,
Nose and Throat specialized clinics (Centre Hospitalier
Universitaire of Montpellier and Lyon). All patients had
permanent hearing loss not caused by infections, expo-
sure to drugs or other prenatal or perinatal etiology of
deafness. Informed consent was obtained for each indi-
vidual. The hearing loss could be moderate to profound,
bilateral or unilateral, symmetrical or asymmetrical, sta-
ble or progressive, pre or post-lingual, syndromic or non
syndromic. From family histories, 79 patients were classi-
fied as sporadic cases, 54 defined as familial cases, includ-
ing 33 with autosomal recessive, 19 with autosomal
dominant, one with X-linked and one ambiguous modes
of inheritance. Seven families were consanguineous. For
26 patients, family histories were unknown.
Among these 159 families, 84 were affected with a non
syndromic, stable, bilateral, congenital, mild to profound
deafness: 55 families had a single deaf child and the oth-
ers, considered as familial cases, showed an autosomal
recessive (24 cases), dominant (4 cases) or unclear (1)
mode of inheritance. Hearing loss was moderate in 4 fam-
ilies, mild in 17, severe to profound in 60 and observed
with variable expression in 3 families.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/5
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Audiological assessment
Pure-tone audiometry (PTA) was performed on every
affected family member. PTA was performed for air con-
duction on each ear using an Interacoustics audiometer.
Air-conduction thresholds were obtained at 0.5, 1, 2, 3, 4,
6 and 8 kHz. Severity of deafness was defined as mild (20–
40 dB HL), moderate (41–70 dB HL), severe (71–90 dB
HL) or profound hearing loss (above 90 dB HL). In young
children, behavioral audiometry was used to determine
the auditory thresholds in free field conditions. All sub-
jects had an auditory brainstem response (ABR) assess-
ment to determine the hearing loss level for high
frequencies.
DNA extraction from patient WBC and mutation analysis
Blood samples were obtained from deaf patients, and
their parents and sibs (when possible) and DNA was
extracted with the Nucleon BACC3 DNA extraction kit
(Amersham Pharmacia Biotech, Piscataway, NJ).
All samples were tested for the 35delG mutation, the non
coding and coding exons of GJB2 (E1 and E2 respectively)
and for the ∆(GJB6-D13S1830) mutation. The experimen-
tal protocols were as follows: 35delG mutation was
screened by PCR-mediated site-directed mutagenesis
(PSDM assay) as previously described [6,25]. GJB2 was
screened by DHPLC and sequencing analysis as previously
described [25]. To obtain an optimal detection of muta-
tions, some primers have been modified and are as fol-
lows: R1-F: AGTCTCCCTGTTCTGTCCTA, R3-F:
TTCTCCATGCAGCGGCTGGT, R3-R: TGAGCACGGGTT-
GCCTCATC. The 309 kb deletion including most of the
GJB6 gene, ∆(GJB6-D13S1830), was screened by two dif-
ferent PCRs encompassing the deletion breakpoints using
the following primers PCR1: CCACCATGCGTAGCCT-
TAACC /GCAGCAGGTAGCACAACTCT; PCR2: CACT-
GAAGTGGTTTCTTGTGC /TCTGTGCTCTCTTTGATCTC,
revealing breakpoint-junction fragments of 390 and 335
bp, respectively.
DNA extraction from dried bloodspots and mutation 
analysis of GJB2
Guthrie cards were obtained from the GREPAM (Center
for neonatal screening) of Montpellier. All samples were
anonymized and no phenotypic data could therefore be
available. Spots of 3 mm diameter, punched from the
cards, were distributed in 96-well plates and DNA was
extracted using methanol extraction [26]. All experiments
were then set up using the robot BioMEK 2000 (Beck-
man). A first set of 2,777 spots were screened using the
PSDM assay, specific for the 35delG mutation. When
DHPLC technology became available in the laboratory, a
further 3,516 spots were analyzed for the R1' fragment
(covering from the ATG codon to position 230 of the cod-
ing sequence (CDS)). 528 of these 3 516 spots were also
analyzed in the R2 fragment (position 190 to 500 of the
CDS). Pools of 2 DNAs were systematically used for
DHPLC screening, thus eliminating the risk of missing the
detection of a homozygote sample. Any abnormal
DHPLC profile was re-evaluated on individual DNA sam-
ples followed by sequencing analysis.
Statistical analysis
Statistical analyses were performed with the Rv.1.3.1 soft-
ware (The free software Fundation, Inc). Proportion, chi-
square and Fisher exact test were used to test differences
between groups. All p-values were taken to be significant
at <0.05. When observed or expected values were below 5,
a Fisher exact test was performed.
Results
Patients
The analysis of the coding and non coding GJB2 exons
plus the ∆(GJB6-D13S1830) screening allowed us to gen-
otype 30 unrelated individuals with biallelic GJB2 and/or
GJB6 (∆(GJB6-D13S1830)) mutations (Table 1). Clinical
and audiological evaluation showed that 27 of these
patients with biallelic DFNB1 mutations had bilateral
congenital severe or profound NSHL with no evidence of
progressive phenotype. No mutation was identified
among families with an autosomal dominant mode of
inheritance.
Sixteen additional patients carried 2 GJB2 mutations/var-
iants with a controversial pathogenic effect or a single
GJB2 sequence variation (Table 2).
A total of 21 different GJB2  sequence variations (1 in
frame deletion, 5 nonsense, 4 frameshift, 8 missense, 1
splicing, 1 in the 5' untranslated region (UTR) and 1 in the
intron 1(IVS1)) were found in 46 unrelated subjects from
the cohort presented here. All were previously reported
with the exception of the C64X (c.192 C>A) mutation, the
-34T>G and IVS1-12C>T sequence variations (Tables 1
and 2). Ten subjects were 35delG homozygotes, 2 were
∆(GJB6-D13S1830) homozygotes. All the other patient
mutations were found in the compound heterozygous
state, with the 35delG accounting for 35/60 (58.3 %) of
the GJB2/GJB6 mutated alleles (Table 1).
∆(GJB6-D13S1830) is the second most frequent mutation
(9/60) and accounts for 15 % of the mutated alleles: in
addition to the 2 homozygotes patients, 5 patients were
identified as compound heterozygotes ∆(GJB6-
D13S1830) /GJB2 mutation.
We assessed the polymorphism 765C>T (referred to as
SNP1 [27]) in 159 unrelated patients (see Table 3). The
frequencies of the genotypes 765C>C, C>T, T>T in control
samples (with no GJB2 sequence variations, N = 113) areBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/5
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57.5 %, 39.8 % and 2.7 % respectively. However, all alle-
les carrying the 35delG mutation (n = 38) and the 309 kb
GJB6  deletion (n = 9) were associated with the 765T
variant.
Parents of deaf individuals
No de novo mutations were detected in patients, as every
parent of patients carrying bi-allelic GJB2/GJB6 mutations
was heterozygous for one of the mutations. In two unre-
lated families, 2 normal-hearing parents of children geno-
typed R127H/M34T or R127H/W24X, were found to be
homozygous R127H. Interestingly, in each of these fami-
lies, a normal-hearing sib also carried the genotype
R127H/M34T or R127H/W24X. Thus, R127H may not be
associated with deafness.
Analysis in the general population
Twenty-two different GJB2 sequence variations (lying in
R1' and R2) were identified in the general population and
are listed in table , together with the calculated carrier fre-
quencies. Ten of these sequence variations were detected
more than once (35delG, M34T, V37I, V27I, W24X, E47X,
Y68C, R127H, V153I, F83L), with relative frequencies
Table 1: DFNB1 genotypes identified in 30 patients with deafness
Number of families Genotype Degree of deafness Mode of inheritance**
10 35delG/35delG 10 profound 5 SC; 4 AR; 1cAR; 1un
2 35delG/E47X 2 profound 2AR
2 35delG/312del14 1 profound, 1 moderate 1AR
1 35delG/N206S 1 moderate 1AR
1 35delG/R184P 1 profound 1 SC
1 35delG/W24X 1 profound 1AR
1 35delG/C64X* 1 profound 1 SC
1 35delG/delE120 1 moderate 1AR
1 35delG/Q57X 1 profound 1SC
1 35delG/R143W 1 profound 1SC
1 35delG/W44X 1 profound 1SC
1 290insA/IVS1+1G>A 1 profound 1AR
33 5 d e l G / ∆(GJB6/D13S1830) 3 profound 1 SC; 1AR; 1un
2 ∆(GJB6/D13S1830)/∆(GJB6/
D13S1830)
2 profound 1 SC; 1 AR
1E 4 7 X / ∆(GJB6/D13S1830) 1 profound 1un
1 235delC/∆(GJB6/D13S1830) 1 profound 1 AR
top: genotypes of the 23 familieswith GJB2 biallelic mutations; bottom: 7 families with DFNB1 mutations All cases presented bilateral, congenital 
hearing loss with no evidence of progression * novel mutation ** SC: Sporadic case; AR: autosomal recessive; cAR: autosomal recessive with 
consanguinity; un: unknown
Table 2: GJB2 genotypes with unknown consequences in 16 families
Number of families Genotype** Hearing loss**** Mode of inheritance
3 35delG/+ 1P progressive; 1M; 1U 1SC,1AR, 1un
2 R127H/M34T 2P 1AR,1SC
1 R127H/W24X P to M *** 1AR
1 M34T/V37I 1 mild 1SC
2 M34T/+ 1 mild, 1M 2AD
1 (IVS1-12C>T)2*/-34T/G* P un
2 IVS1-12C>T*/+ 1P progressive, 1P 1SC, 1un
2 V37I/+ 1M, 1P 1AR, 1un
1 V153I/+ M 1SC
1 G160S/+ P 1SC
* novel sequence variant ** + designates the wild type allele *** variable phenotype within the family **** P: profound; M: moderate; U: unilateral; 
un: unknownBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/5
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ranging between 2,3 % to 0,09 % and 7 of these were not
previously reported (Y68C, IVS1-7G/A, G4D, Q7Q, T26T,
H67R, D159D).
The M34T variant is the most frequent, with a carrier fre-
quency of 1/43 (2.3 %). In addition, among the 3 516
dried bloodspots screened, one homozygote M34T/M34T
was detected.
Table 3: Distribution of the C765T polymorphism among patients
35delG
C/C C/T T/T p-values
Patients 35delG/35delG 00 1 0 p  <  1 0 -6
Patients 35delG/other 01 35
Controls 65 45 3
∆(GJB6/D13S1830)
C/C C/T T/T p-values
Patients ∆(GJB6/
D13S1830)/∆(GJB6/
D13S1830)
002 p  <  1 0 -6
Patients ∆(GJB6/
D13S1830)/other
032
controls 65 45 3
Controls: patients with no GJB2 mutation. Chi-square test was used to test the independence between the genotype 765T/T and the control group.
Table 4: Frequencies of the sequence variations identified in the general population from Languedoc-Roussillon.
Name Nucleotide change Number of alleles Number of 
chromosomes 
tested
Allele frequencies 
in % (95 % CI)
Carrier frequencies 
in % (95 % CI)
M34T 101T>C 81 7 032 1.15 (0.92–1.44) 2.3 (1.83–2.86)
35delG c.35delG 96 12 586 0.76 (0.62–0.93) 1.53 (1.24–1.85)
R127H 380G>A 7 1 056 0.66 (0.29–1.42) 1.33 (0.58–2.82)
V37I 109G>A 30 7 032 0.43 (0.29–0.62) 0.85 (0.58–1.24)
V153I 457G>A 4 1 056 0.38 (0.12–1.04) 0.76 (0.14–1.79)
F83L 249C>G 3 1 056 0.28 (0.07–0.90) 0.57 (0.14–1.79)
V27I 79G>A 10 7 032 0.14 (0.07–0.27) 0.28 (0.14–0.58)
E114G 341A>G 1 1 056 0.09 (0.005–0.61) 0.19 (0.009–1.22)
DelE120 358-360delGAG 1 1 056 0.09 (0.005–0.61) 0.19 (0.009–1.22)
G160S 478G>A 1 1 056 0.09 (0.005–0.61) 0.19 (0.009–1.22)
D159D* 477C>T 1 1 056 0.09 (0.005–0.61) 0.19 (0.009–1.22)
W24X 71G>A 5 7 032 0.07 (0.03–0.18) 0.14 (0.06–0.36)
E47X 139G>T 4 7 032 0.06 (0.02–0.16) 0.11 (0.04–0.32)
Y68C* 203A>G 3 7 032 0.04 (0.01–0.14) 0.09 (0.02–0.28)
W44X 132G>A 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
R32H 95G>A 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
S19T 56G>C 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
IVS1-7G>A* 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
G4D* 11G>A 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
Q7Q* 21G>A 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
T26T* 78C>T 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
H67R* 200A>G 1 7 032 0.014 (0.007–0.092) 0.03 (0.01–0.18)
*: novel sequence changes.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/5
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The 35delG mutation was screened in a total of 6,293
newborns (2,777 were analyzed by PSDM and 3,516 by
PCR-DHPLC). Ninety-two 35delG heterozygotes and 2
35delG homozygotes were identified, resulting in a carrier
frequency of 1/66 (1.53 %) for 35delG.
In addition, 3 individuals were compound heterozygotes
(M34T/35delG, V37I/G160S and V27I/E114G) for GJB2
sequence variants.
We also present the allelic frequencies of some GJB2
mutations in individuals referred for NSHL with respect to
the frequency in the general population (Table 5). We
could not detect any significant difference between the
two groups for the V37I, R127H and M34T sequence
variations.
Discussion
The 35delG mutation in patients and in general 
population
Thirty families were clearly genotyped with causative
mutations in GJB2/GJB6. Homozygosity for 35delG was
found in 33.3 % (10/30) of the genotyped unrelated deaf
patients, 50 % were carrying this deletion in a compound
heterozygous state and 16.7 % had other mutations. The
35delG accounts for 58.3 % (35/60) of the DFNB1
mutated alleles in these families. As in previous studies,
this study shows an important implication of GJB2 in non
syndromic prelingual hearing loss. However, we have
observed a lower frequency of the 35delG mutant allele
and a higher heterogeneity of other mutations than in pre-
vious studies [28-30].
Our study region (Languedoc Roussillon) shows a signifi-
cantly higher carrier rate of the 35delG (1.53 % – 1/66),
compared to the North-East part of Europe (0.9 % – 1/110
among 1,212 controls) [31] and a lower carrier rate com-
pared to other south European areas such as Spain (2.31
% – 1/43) [7], Italy (3.45 % – 1/32) [23] and Greece (3.54
% – 1/28) [32]. The epidemiologic study presented here is
based on the largest number of random samples describ-
ing an unbiased general population screen and once more
supports the heterogeneous composition of the Langue-
doc Roussillon population. This situation has direct
implications for genetic counseling as well as on the
development of potential diagnostic kits (as it was in the
case for the design of the CF neonatal screening kit [24]).
The explanation for such a different carrier rate lies in the
heterogeneity of the migrations "landing" in Languedoc
Roussillon, historically and still today. A recent study, car-
ried out on the prevalence of Hemochromatosis gene
(HFE) mutations in the Languedoc Roussillon population
has annotated the origins of the four grand-parents for
each newborn. It was observed that the population origi-
nated from various regions in France and also from other
European or African countries [33].
Other sequence variations in the GJB2 gene
35delG remains by far the most frequent mutation in the
hearing impaired population, although its frequency is
lower than was expected in comparison with other Medi-
terranean areas. The second most common mutation in
our region is the ∆(GJB6-D13S1830) with 15 % of the
mutated alleles, and the E47X mutation represents 5 %.
The other mutations were identified twice or only once.
This genetic heterogeneity is emphasized by the number
of sequence variations observed in both the patient and
general population. Ninety variations have been reported
[5]. In this study, besides 35delG and ∆(GJB6-D13S1830),
we describe 33 sequence variations, 10 for the first time (-
34T>G, IVS-12C>T, IVS1-7G>A, G4D, Q7Q, T26T, C64X,
H67R, Y68C, D159D tables 1, 2, 4). The pathogenicity of
11 of these has been previously well established (E47X,
312del14, 290insA, IVS1+1G>A, W24X, W44X, delE120,
Q57X, R143W, W44X, 235delC). As well, the novel muta-
tion C64X described in this study results in a truncated
protein with pathogenic consequences. Of the 21 other
sequence variations observed, four were previously
reported as recessive mutations (R32H, S19T, N206S,
Table 5: Comparison of the allelic frequencies of GJB2 sequence variations in unrelated french patients with NSHL and in the general 
population
GJB2 Sequences 
variations
Number of unrelated chromosomes Significance (p-values)
patients (n = 318) general population
35delG 38 11.9 % 96/12586 0.76 % S (p < 10-6)
M34T 5 1.6 % 81/7034 1.15 % NS (p = 0.66)
R127H 3 0.94 % 7/1056 0.66 % NS (p = 0.89)
V37I 3 0.94 % 30/7034 0.43 % NS (p= 0.36)
-: not studied; S: significant difference; NS: no significant difference. P-values significant at <0.05BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/5
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R184P), five are known non pathogenic variants (V27I,
F83L, E114G, V153I, G160S), three of them are silent
(D159D, Q7Q, T26T), six have unknown consequences (-
34T>G, IVS1-12C>T, IVS1-7G>A, G4D, H67R, Y68C) and
three are still controversial (M34T, V37I, R127H and see
below). Three of the newly identified sequence variations
are in the noncoding region. According to splicing predic-
tion programs, both IVS variations should be silent. Inter-
estingly, the IVS1-12C>T was found in a homozygous
state in a patient originating from Guadeloupe with one
IVS1-12C>T variation allelic to the -34T>C variation. This
T to C transition has yet unknown consequences on the
regulation of the GJB2 gene.
Founder effects and sequence variations
A founder effect for the 35delG mutation has recently
been described [27], which explains the variable fre-
quency of this mutation in different populations rather
than resulting from a mutational hot spot. Similarly, the
235delC mutation, frequent in the Japanese population,
is derived from a common ancestor [34]. Founder effects
may account for a number of other GJB2 sequence varia-
tions, whose frequencies depend on ethnic background
(such as M34T [4]). The polymorphism 765C>T (referred
to as SNP1 [27]) has been systematically included in our
series. The 765T allele showed complete association with
the 35delG as well as the ∆(GJB6-D13S1830). The geno-
type comparison between GJB2  and/or  ∆(GJB6-
D13S1830) patients with GJB2 negative subjects is signif-
icant with P-values < 10-6 (Table 3). These results are in
accordance with the fact that ∆(GJB6-D13S1830) is absent
in some populations and strongly suggest the existence of
a founder effect as confirmed by a recent multicenter
study [17].
Controversial effects of sequence variations
Among the sequence variations that have controversial
consequences, a few variants have been extensively dis-
cussed based on families with deafness and on studies
using in vitro expression systems. Since we have performed
a population based study, in parallel with the analysis of
a number of hearing impaired patients, we show that
M34T, V37I and R127H represent common variants that
are not responsible for severe or profound deafness.
The M34T variation was first described as a dominant
mutation [35] and the dominant negative effect was sup-
ported by in vitro functional studies [36,37]. However, the
description of normal hearing carriers abolished this
hypothesis and furthermore, normal hearing patients
were found to be compound heterozygotes, M34T/
167delT or M34T/35delG [29,38]. Since the two alleles in
trans of the M34T corresponded to a null allele, Griffith et
al. (2000) suggested that the M34T was functional in vivo
and therefore, the phenotypic consequences of the M34T
allele would depend on the opposing CX26 allele variant
[39]. The possibility of considering the M34T as a non
pathogenic variant was also raised [40,41].
M34T represents the highest carrier rate in our popula-
tion. We do not deal with a carrier rate of 1/116 as esti-
mated from a small sample in Paris [29,41] but with 1/43
(2.3 %). We identified one M34T homozygote in the gen-
eral population, as expected from the carrier frequency (1/
4,444). The M34T is more frequent than the 35delG and,
in contrast to the 35delG mutation, no M34T homozygote
or in compound heterozygosity with a deleterious muta-
tion was observed in our cohort of patients. This carrier
rate is similar to the one observed by Green et al. [9]. The
allele frequency of 1.15 %, based on 3,516 individuals,
shows no significant discrepancy with the M34T allele fre-
quency in the deaf population (1.6 %). Although a study
based on the general population does not rule out the
possibility of hearing deficiency in few individuals, these
data eliminate the possibility of considering the M34T as
a dominant or recessive mutation associated with severe
or profound deafness.
The R127H, first described by Estivill [7] is also conten-
tious and functional studies of this variant are inconsist-
ent [42,43]. The frequency of carrier rate of in our region
is 1/75 (1.33 %), not significantly different from that of
the deaf population. Moreover, two normal-hearing par-
ents were genotyped R127H/R127H.
Finally two normal-hearing sibs were compound hetero-
zygotes R127H/M34T or R127H/W24X emphasizing the
non pathogenic nature of this sequence variation. How-
ever, the genotype R127H/M34T was identified twice in
our patient cohort (2/159 1.25 %) but never in the general
population (odds to be associated randomly of 1.5 × 10-
4). The observed frequency in the patients is significant (p
= 1.3 %), and therefore we still cannot rule out that the
combined genotype R127H/M34T can act as a variant
that, under certain circumstances (associated with other
modifiers such as alterations in other deafness genes),
would contribute to the phenotype.
Similarly, the V37I variation does not show any signifi-
cant difference in frequency between the general and deaf
populations. This is consistent with the fact that it was
originally identified as a non pathogenic polymorphism
because of its occurrence in a heterozygous state in the
general population [40,44]. However, homozygosity for
V37I and compound heterozygosity of V37I were often
described in patients with NSHL suggesting that V37I acts
as a recessive mutation. Recent studies [11,28,45,46]
clearly indicated its pathogenicity when associated with
another mutated GJB2  allele. Functional analyses [47]BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/5
Page 8 of 10
(page number not for citation purposes)
also showed that V37I is devoid of functional activity and
thus may be pathogically significant.
The likelihood of M34T to be associated with V37I is 1 ×
10-4, as calculated from the allele frequency, and is signif-
icantly different from the observed frequency in patients
(p = 0.63 %), and once more can not rule out that the gen-
otype M34T/V37I is not associated with mild or moderate
deafness.
These data demonstrate the challenge of interpretating the
association of two sequence variations. Moreover, com-
bined genotypes with variants such as M34T, V37I, or
R127H could have a phenotypic expression modulated by
environmental factors or modifier genes. Conclusions
from in vitro transfection assays can not be taken as com-
plete because one sequence variant supposedly acting as a
recessive mutation should be at least co-transfected with a
second recessive mutation; but above all, one wonders
whether the different cell types used for these in vitro
experiments really reflect the molecular context existing in
vivo. Complementary assays considering co-transfection
of two different mutations need to be performed. These,
together with compilation of observed combined geno-
types correlated with phenotypes, should help in the
interpretation of the molecular tests.
Phenotypes associated with GJB2/GJB6 mutations
Although a recent report recommended GJB2 screening in
cases of progressive and recurrent sudden HL [31]), no
GJB2 and/or GJB6 biallelic mutations were identified in
patients with progressive, postlingual, asymmetrical hear-
ing loss in this study. The contribution of the GJB2/GJB6
genes, in our cohort is exclusively found in non syndro-
mic, prelingual, bilateral, stable deafness and is about 33
% (28/84). This is similar to the proportion found in
Spain (31.6 %) [28], in France (39.8 %) [48] and in
Greece (33.3 %) [30]. However the degree of implication
of GJB2/GJB6 genes in deafness depends on the composi-
tion in degree of severity of the patient group. In this
study, the rate of DFNB1-associated deafness would be
41.6 % (25/60) if only congenital profound NSHL was
considered.
Conclusions
The data presented here demonstrate that genetic coun-
seling has been greatly improved with the identification of
the ∆(GJB6-D13S1830) mutation and a total of 30 fami-
lies could benefit from a GJB2 and/or GJB6 unambiguous
molecular diagnosis. The genetic counseling was more dif-
ficult for 16 families (1/3) because of the compound het-
erozygosity of poorly-defined variations or the presence of
a single GJB2 alteration. Additional data certainly need to
be collected to evaluate if two sequence variations consid-
ered as non-disease causing stay neutral when associated
in trans.
The number of families (129) for which no genetic coun-
seling could be provided, based on the mutation screen-
ing of the DFNB1 genes, remains very high and
demonstrates that criteria for genetic testing must be very
well defined and set according to the provided test
(CX26). Genetic heterogeneity is still observed when
prelingual, non syndromic, stable deafness is present, and
the possibility for screening mutations in other genes
should be offered.
Finally, neonatal screening programs bring a great
improvement in the management of deafness; however,
the option to offer molecular based screening remains
very uncertain and if offered should be based on specific
population studies because of the genetic heterogeneity of
deafness.
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